Weight Gain Linked to HIV Treatment in Lancet Series
A paper in The Lancet HIV Series examines rising weight gain among people living with HIV and the role of weight stigma in their care.
Updated on Nov. 10, 2026 in Weight Loss
Live Poll
Do you trust doctors to treat patients with higher body weight fairly?
Researchers published a paper in The Lancet HIV Series on weight gain in people living with HIV, reporting that newer integrase inhibitor-based therapies are consistently associated with greater weight gain than older regimens. The paper was published on 8 November 2026.
Why it matters
Weight gain among people living with HIV is associated with rising burdens of hypertension and diabetes, and weight stigma is associated with poorer mental health and avoidance or delay of care. Whether weight stigma affects adherence to antiretroviral therapy remains poorly understood.
The Lancet HIV Series review reports that integrase inhibitor-based regimens, including those combined with tenofovir alafenamide, are associated with greater weight gain than older regimens, with the largest increases among Black women. Whether weight stigma affects treatment adherence is still poorly understood.
The players
The Lancet HIV Series
A journal series published by The Lancet that examines HIV research, care, and policy across global health contexts.
The details
The paper highlights that weight stigma is commonly framed as a failure of personal willpower despite the roles of genetics, metabolic differences, medications, food environments, and structural poverty. The authors note that HIV care has moved from standalone clinics toward integration into primary care in many countries, and that community-led, integrated services may help address both HIV and weight stigma.
Timeline
8 November 2026: Paper published as part of The Lancet HIV Series.
Health Landscape
The paper sits within the broader shift of HIV care from standalone clinics toward integration into primary care, a trend the Lancet HIV Series documents across many countries. It reflects growing recognition that metabolic conditions such as obesity and diabetes now shape long-term outcomes for people living with HIV.
People living with HIV on newer integrase inhibitor-based regimens may experience greater weight gain, which can raise the risk of hypertension and diabetes. Clinicians and patients may need to monitor weight and metabolic health alongside viral suppression.
The takeaway
Addressing weight stigma alongside HIV treatment may improve mental health and encourage people to stay engaged with care. Integrated, community-led services offer a practical model for managing both conditions together.
Further reading
Explore more on weight loss to see how metabolic changes and stigma affect long-term health.
Source note: This article includes information reported by Wits.
Live Poll
Do you trust doctors to treat patients with higher body weight fairly?
